Inhibition of Ileal Na⁺/Bile Acid Cotransporter by S-8921 Reduces Serum Cholesterol and Prevents Atherosclerosis in Rabbits

From Discovery Research Laboratories II, Shionogi & Co, Ltd, Toyonaka, Osaka, Japan.

Correspondence to Seijiro Hara, PhD, Developmental Research Laboratories, Shionogi & Co, Ltd, 3-1-1, Futaba-Cho, Toyonaka, Osaka 561-0825, Japan. E-mail seijiro.hara{at}shionogi.co.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—The ileal Na⁺/bile acid cotransporter (IBAT) plays an important role in the enterohepatic circulation of bile acids. We investigated the effects of IBAT inhibition on the maintenance of serum cholesterol level by using a novel IBAT inhibitor, S-8921, in rabbits. Administration of S-8921 by its incorporation into the diet (0.01% to 0.1%) for 1 to 2 weeks in heterozygous Watanabe heritable hyperlipidemic rabbits decreased serum cholesterol by 29% to 37% and increased fecal excretion of measured bile acids by 60% to 180% compared with control rabbits. Liver microsomal cholesterol 7-hydroxylase and 3-hydroxy-3-methylglutaryl coenzyme A reductase activities were increased by 75% to 84% and 84% to 89%, respectively, with S-8921 treatment. S-8921 administration (0.1% in the diet) to normal New Zealand White rabbits for 2 weeks resulted in increased hepatic low density lipoprotein receptor expression, which was assessed by Northern blot analysis. In cholesterol-fed New Zealand White rabbits, S-8921 treatment (0.003% to 0.1% in the diet) for 10 weeks dose-dependently inhibited the development of hypercholesterolemia. It also inhibited the accumulation of cholesterol in the aortic arch and reduced the severity of coronary atherosclerosis. These results indicate that IBAT inhibition by S-8921 affects serum cholesterol, liver enzymes, low density lipoprotein receptor activity, and atherosclerosis in the same manner as bile acid sequestrants. We suggest that an IBAT inhibitor such as S-8921 could be useful in the treatment of hypercholesterolemia.

Key Words: ileal bile acid cotransporter • serum cholesterol • S-8921 • LDL receptor • cholesterol 7-hydroxylase

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Hypercholesterolemia has been recognized as a major risk factor for coronary heart disease (CHD). In clinical trials, reducing serum LDL cholesterol has been demonstrated to decrease the incidence of CHD and to reverse atherosclerotic lesions.^{1 2 3 4} Two main classes of clinically useful hypocholesterolemic agents are the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the bile acid sequestrants. Both induce hepatic LDL receptor activity by increasing hepatic cholesterol demand.^{5 6 7 8} Because the major determinant of serum cholesterol level is hepatic LDL receptor activity,⁹ these agents share a common mechanism leading to reduction of cholesterol.

In the case of bile acid sequestrants such as cholestyramine and colestipol, they are nonspecific anion-exchange resins, and patients have complained of their bulkiness.¹⁰ The mechanism of action of a bile acid sequestrant is to inhibit the enterohepatic circulation of bile acids. Bile acids are synthesized from cholesterol in the liver and secreted into the bile flow to facilitate the digestion and absorption of lipids, followed by nearly quantitative reabsorption from the intestine.¹¹ The ileal Na⁺/bile acid cotransporter (IBAT) maintains the reabsorption of bile acids from the intestine,^{12 13} and thus, its inhibitor is expected to exhibit pharmacological effects similar to those of bile acid sequestrants.

Some compounds have been shown to inhibit IBAT in vitro and to decrease serum cholesterol in vivo in rats loaded with cholesterol and bile acid or in cholesterol-fed guinea pigs.^{14 15} Recently, we reported that a new IBAT inhibitor, S-8921, could markedly decrease serum cholesterol in non–cholesterol- and bile acid–loaded normal hamsters¹⁶ as well as in cholesterol- and bile acid–loaded rats.¹⁷ However, only limited knowledge concerning the impact of IBAT inhibition on cholesterol metabolism is available at present. In this study, we investigated the mode of action of S-8921, a novel IBAT inhibitor, by using several rabbit models to evaluate the efficacy of an IBAT inhibitor as a hypocholesterolemic and antiatherosclerotic agent and to clarify the mechanisms leading to cholesterol reduction after IBAT inhibition.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Chemicals
S-8921 [methyl-1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate] was synthesized at Shionogi Research Laboratories. Cholestyramine was purchased from Sigma Chemical Co. DL-3-[3-¹⁴C]HMG- CoA (2.2 GBq/mmol), [1-¹⁴C]oleoyl CoA (2.1 GBq/mmol), [1,2,6,7-³H(N)]cholesteryl oleate (2886 GBq/mmol), and Na¹²⁵I (644 GBq/mg) were from Dupont–New England Nuclear.

Animals
Male heterozygous Watanabe heritable hyperlipidemic (WHHL) rabbits (8 weeks old) and male New Zealand White (NZW) rabbits (18 or 9 weeks old) were obtained from Kitayama Labes Co, Ltd (Nagano, Japan). They were housed individually in metal cages and given standard chow pellets (LRC-4 for WHHL rabbits and RC-4 for NZW rabbits; Oriental Yeast Co, Ltd) and water ad libitum for 2 weeks before the experiments began. During the experimental period, 100 g of chow pellets per day was given to each animal, and water was given ad libitum. The animals were fasted overnight before they were killed. On the day that they were killed, the animals were bled from the abdominal vein under pentobarbital anesthesia. All animal experiments were approved by the Shionogi Animal Care and Use Committee.

Experimental Design
Study With Heterozygous WHHL Rabbits
Eighteen heterozygous WHHL rabbits (10 weeks old) were divided into 3 groups (n=6 each) so that each group had a similar baseline serum cholesterol concentration. Next, the animals were either kept on the control diet or switched to a diet supplemented with S-8921 at concentrations of 0.01% and 0.1% (corresponding to 4.0 to 4.6 and 42 to 47 mg/kg, respectively) for 2 weeks. Blood samples were collected from the marginal ear vein to determine serum lipids at 0, 1, and 2 weeks of the study without fasting. Feces were collected over 24 hours and lyophilized to measure bile acid contents at 2 weeks of the study. The liver was immediately removed after the animal was killed, and its microsomal fraction was prepared.¹⁸ The microsomal fractions were stored at -80°C until determination of enzyme activities. Their protein contents were determined as described¹⁹ by using BSA as a standard.

Study With Normal NZW Rabbits
Eight NZW rabbits (20 weeks old) were divided into 2 groups (n=4 each) so that each group had a similar baseline serum cholesterol concentration. The animals were either kept on the control diet or switched to a diet supplemented with S-8921 at a concentration of 0.1% (corresponding to 31.1 to 31.4 mg/kg) for 2 weeks. Blood samples were collected from the marginal ear vein after overnight fasting on the day before diet administration and on the day that the animals were killed. After euthanasia, the liver was immediately perfused with 120 mL of ice-cold saline through a cannulated portal vein. Small pieces of tissues were rapidly frozen in LN₂ and stored at -80°C until RNA extraction. Other pieces of liver tissue (2 g) were resected and homogenized with a Physcotron homogenizer. Four samples from each group were combined, and the membranes that sedimented between 8000g and 100 000g were prepared and stored in LN₂ until the¹²⁵I-LDL binding assay.²⁰

Study With High-Cholesterol Diet–Fed (HCD) NZW Rabbits
Thirty-seven NZW rabbits (11 weeks old) were fed a diet containing 0.5% cholesterol (high-cholesterol diet; HCD) for 1 week. They were then divided into 6 groups so that each group had a similar serum cholesterol concentration. The animals were either continued on the HCD (n=7) or switched to an HCD supplemented with S-8921 at concentrations of 0.003%, 0.01%, 0.03%, and 0.1% (corresponding to 1.0 to 1.2, 3.3 to 4.2, 10 to 12, and 33 to 42 mg/kg, respectively; n=6) or with cholestyramine at a concentration of 1.5% (corresponding to 510 to 640 mg/kg; n=6) for 10 weeks. Blood samples were collected from the marginal ear vein every other week without fasting. The liver, heart, and aorta were removed after the animals were killed. A small piece of liver was stored at -20°C until the determination of lipid contents was made. The heart and longitudinally opened aorta were fixed in 10% phosphate-buffered formalin until evaluation of atheromatous plaque and the determination of cholesterol contents. Four NZW rabbits were fed an ordinary diet (RC-4) throughout the experimental period, killed, and then treated as described above.

Analysis of Lipids and Bile Acids
Serum Lipids
Serum total cholesterol, triglyceride (TG), and phospholipid were determined by using commercial kits Sterozyme Auto-545 (Fujirebio, Inc), L-type Wako TG·H, and L-type Wako PL·H (Wako Pure Chemical Industries), respectively. Serum lipoprotein fractions were separated by ultracentrifugation.²¹ VLDL was determined as the d<1.006 g/mL fraction, and HDL was determined as the d>1.063 g/mL fraction. LDL was calculated by subtracting the d>1.063 g/mL fraction from the d>1.006 g/mL fraction.

Lipids in the Liver and Aorta
The liver was homogenized with ethanol, and then lipid extraction was performed by refluxing for 20 minutes.²² The extract was evaporated under N₂ gas and dissolved with isopropanol. The contents of total and free cholesterol, TG, and phospholipid were determined by using commercial kits Determinar TC 555 and Determinar FC 555 (Kyowa Medex Co, Ltd), triglyceride E-test (Wako), and phospholipid B-Test (Wako), respectively. Lipid measurement was performed with a Cobas-Fara centrifugal analyzer (Roche Diagnostics). Esterified cholesterol was calculated by subtracting free cholesterol from total cholesterol. The aorta was frozen in LN₂ and pulverized. Lipids were extracted from these samples with chloroform-methanol (2:1, vol/vol)²³ and filtered. The contents of total and free cholesterol were determined as described above.

Fecal Bile Acids
Bile acids were obtained from the lyophilized feces after 3 ethanol extractions²⁴ and purified with piperidinohydroxypropyldextran gel (Shimadzu Corp). These samples were analyzed by high-performance liquid chromatography (HPLC).²⁵ The amounts of the 3 major bile acids (12-oxolithocholic acid, deoxycholic acid, and lithocholic acid)^{26 27 28} were determined and summed.

Activity of Liver Microsomal Enzymes
Cholesterol 7-Hydroxylase
Cholesterol 7-hydroxylase activity in microsomes was measured by the HPLC method.²⁹ 7-Hydroxycholesterol generated from endogenous cholesterol during the incubation of microsomes for 15 minutes at 37°C was labeled with 1-anthroyl cyanide (Wako), and its content was quantified by HPLC with fluorometric detection.

HMG-CoA Reductase
HMG-CoA reductase activity in microsomes was determined as described elsewhere.³⁰ Microsomes were incubated with [3-¹⁴C]HMG-CoA for 30 minutes at 37°C, and the generated [¹⁴C]mevalonic acid was converted to mevalonolactone. After separation of [¹⁴C]mevalonolactone by thin-layer chromatography, radioactivity was determined by liquid scintillation counting.

Acyl CoA:Cholesterol Acyltransferase (ACAT)
ACAT activity in microsomes was determined by using endogenous cholesterol and exogenous [1-¹⁴C]oleoyl CoA as the substrates.³¹ [¹⁴C]Cholesteryl oleate generated during incubation of the reaction mixture, including the microsomes, for 5 minutes at 37°C was separated by thin-layer chromatography, and its radioactivity was determined. [1,2,6,7-³H(N)]Cholesteryl oleate was used as the internal standard.

Hepatic LDL Receptor (LDLR) Expression
Northern Blot Analysis
Total cytoplasmic RNA was prepared from rabbit liver according to the acid guanidinium–thiocyanate-phenol-chloroform method.³² Cytoplasmic RNA (30 µg per lane) was electrophoretically separated in a denatured 1.0% agarose gel and transferred to a nylon membrane. The membrane was hybridized to a ³²P-labeled synthetic oligonucleotide probe for the LDLR [LR55, 5'-GCCAC(A/G)TCATCCTC CAGGCTGACCATCTGTCT(C/T)GAGGGGTAGGTGTAGCCGTCCT-3'] or a human GAPDH cDNA probe (CLONTECH Laboratories, Inc) overnight at 65°C in 0.5 mol/L sodium phosphate (pH 7.5), 10 mg/mL BSA, 1 mmol/L EDTA, and 7% SDS, followed by 2 washes for 30 minutes at 65°C in 2x SSC (1x SSC is 0.16 mol/L NaCl and 0.016 mol/L sodium citrate) and 0.1% SDS. Bands corresponding to LDLR and GAPDH in an autoradiographic film of the probed membrane were densitometrically quantified and normalized as the ratio of LDLR to GAPDH.

¹²⁵I-LDL Binding Assay
Rabbit LDL (d=1.019 to 1.063 g/mL) was isolated from the plasma of fasted rabbits by differential ultracentrifugation.³³ LDL was radioiodinated by the iodine monochloride method.³⁴ The binding assay of¹²⁵I-LDL to liver membranes was conducted at 4°C as described.^{20 35} EDTA-sensitive binding, which was calculated by subtracting the amounts of ¹²⁵I-LDL bound in the presence of EDTA (10 mmol/L) from that bound in the absence of EDTA, was considered to be specific for the LDLR.

Evaluation of Atheromatous Plaque
Aortic Lesions
The fixed aorta was cut into 3 segments (aortic arch, thoracic aorta, and abdominal aorta), and each intimal surface was photographed. Enlarged prints of the photographs were analyzed with an image analyzer (Cosmo Zone ISA system, Nikon). Total surface area and the area covered with plaque were determined, and the percentage of the atheromatous plaque area was calculated.

Coronary Artery Lesions
The fixed heart was cut into cross sections at 5-mm intervals. Five cross sections from each heart were embedded in paraffin. The samples were stained with elastica–van Gieson's stain. All coronary arteries visible in the 5 cross sections from each heart (average, 110 arteries) were analyzed by using the image analyzer (Cosmo Zone), and the severity of intimal thickening was classified into 3 levels: none or mild, 0% to 30% stenosis; moderate, 31% to 60% stenosis; and severe, 61% to 100% stenosis. The percentage of each stenosis level was calculated.

Statistical Analysis
Data are expressed as mean±SE. Statistical significance of differences was determined by using Student's t test, paired t test for paired data between two groups, or Dunnett's multiple comparison test when more than 3 groups were compared. P values <0.05 and <0.01 were considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
General Results
All animals treated with S-8921 in this report were in good health throughout the study, and apparent side effects such as diarrhea were not observed in S-8921–treated animals as well as control animals.

Study With Heterozygous WHHL Rabbits
To confirm the ability of S-8921 to inhibit IBAT in vivo in the rabbit model, we first characterized the effect of S-8921 administration on heterozygous WHHL rabbits. Food consumption during the 2-week experimental period in each group was 100%. The body weight of the rabbits was not affected by S-8921 treatment (Table 1). S-8921 treatment for 1 to 2 weeks caused a decrease in serum total cholesterol concentrations, with 0.01% S-8921 (4.0 to 4.6 mg/kg) being almost maximally effective (Figure 1A). The serum cholesterol decrease was accompanied by increased fecal excretion of measured bile acids (Figure 1B), indicating that this drug could inhibit IBAT in vivo in rabbits. S-8921 treatment for 2 weeks decreased serum cholesterol especially in the LDL fraction but did not affect serum TG and phospholipid concentrations (Table 1).

View larger version (27K): [in this window] [in a new window]   Figure 1. Effects of S-8921 on serum total cholesterol (A) and fecal bile acid contents (B) in heterozygous WHHL rabbits. S-8921 was administered by its incorporation into the diet, and concentrations of 0.01% and 0.1% corresponded to 4.0 to 4.6 and 42 to 47 mg/kg, respectively. Data represent mean±SE of 6 animals. *,**Significantly different from control group at P<0.05, P<0.01, respectively, by Dunnett's multiple comparison test.

The effects of S-8921 on the activities of 3 liver microsomal enzymes are shown in Figure 2. The free cholesterol contents in microsomes of control, 0.01% S-8921, and 0.1% S-8921 groups were 25.9±0.8, 26.1±1.8, and 23.7±2.0 µg/mg protein, respectively, which were not significantly different from each other. S-8921 treatment for 2 weeks clearly increased cholesterol 7-hydroxylase and HMG-CoA reductase activities (Figure 2A and 2B) but did not affect ACAT activity (Figure 2C).

View larger version (35K): [in this window] [in a new window]   Figure 2. Effects of S-8921 on liver microsomal cholesterol 7-hydroxylase (A), HMG-CoA reductase (B), and ACAT (C) activities in heterozygous WHHL rabbits. S-8921 was administered by its incorporation into the diet for 2 weeks, and liver microsomal enzyme activities were determined as described in Methods. S-8921 concentrations of 0.01% and 0.1% corresponded to 4.0 to 4.6 and 42 to 47 mg/kg, respectively. Data represent mean±SE of 6 animals. *,**Significantly different from control group at P<0.05, P<0.01, respectively, by Dunnett's multiple comparison test.

Study With Normal NZW Rabbits
Food consumption during the 2-week experimental period in the control group and the 0.1% S-8921–treated group was 96.5±3.5% and 99.5±0.5%, respectively. The body weight of S-8921–treated rabbits, 3.16±0.08 kg, was not significantly different from that of control animals, 3.20±0.10 kg.

Treatment with S-8921 for 2 weeks decreased serum cholesterol in normal rabbits. The serum total cholesterol value after S-8921 treatment, 0.48±0.06 mmol/L, was significantly lower than that before S-8921 treatment, 0.68±0.09 mmol/L (P<0.01, paired t test). Serum total cholesterol values of the control group were not significantly different before versus after the experiments (data not shown).

Northern blot analysis revealed that the amount of liver mRNA for the LDLR was increased 1.7-fold by S-8921 treatment (Figure 3). The ratio of LDLR to GAPDH in the S-8921–treated group, 0.907±0.077, was significantly higher than that in the control group, 0.522±0.072 (P<0.05, Student's t test). S-8921 treatment also increased¹²⁵I-LDL specific binding to liver membranes. The specific binding of ¹²⁵I-LDL at 1.5 and 6 µg/mL was 2.9 and 5.5 ng/mg protein for the control group and 4.3 and 10.4 ng/mg protein for the S-8921–treated group, respectively. The significance of differences was not determined because we used 1 preparation from each group of rabbits as described in Methods.

View larger version (24K): [in this window] [in a new window]   Figure 3. Induction of hepatic LDLR mRNA by S-8921 in normal NZW rabbits. S-8921 was administered by its incorporation into the diet at a concentration of 0.1%, which corresponded to 31.1 to 31.4 mg/kg for 2 weeks. Northern blot analysis of hepatic LDLR was performed as described in Methods. A, Typical autoradiogram of Northern blotting. B, Densitometric analysis of bands corresponded to LDLR and GAPDH. Data represent mean±SE of 4 animals. *Significantly different from control group at P<0.05 by Student's t test.

Study With HCD NZW Rabbits
In this experiment, treatment with S-8921 and cholestyramine was initiated after feeding of a diet containing 0.5% cholesterol for 1 week. Food consumption during the next 10-week experimental period in control, 0.003% S-8921, 0.01% S-8921, 0.03% S-8921, 0.1% S-8921, and 1.5% cholestyramine groups was 95.4±1.8%, 96.6±2.4%, 97.1±1.9%, 99.6±0.3%, 99.0±0.0%, and 97.3±1.9%, respectively. There were no significant differences between control and drug-treated groups. The body weight of rabbits was not affected by S-8921 and cholestyramine treatment (Table 2). The control group developed further hypercholesterolemia during the experimental period (Figure 4). S-8921 treatment suppressed this effect dose-dependently, and 0.01% S-8921 (3.3 to 4.2 mg/kg) was the minimum dose needed for a significant decrease (Figure 4). A high dose of cholestyramine (1.5%, 510 to 640 mg/kg) moderately suppressed the development of hypercholesterolemia (Figure 4). S-8921 treatment decreased serum cholesterol in the VLDL and LDL fractions and also decreased serum phospholipid, but its effects on TG were not clear (Table 2). An HCD resulted in accumulation of cholesterol in the liver. S-8921 decreased the contents of esterified cholesterol but did not change other lipid contents in the liver (Table 3).

View larger version (28K): [in this window] [in a new window]   Figure 4. Effects of S-8921 and cholestyramine on development of hypercholesterolemia in HCD NZW rabbits. Rabbits were fed a diet containing 0.5% cholesterol for 1 week. After that, S-8921 and cholestyramine were administered by their incorporation into the HCD for another 10 weeks. S-8921 concentrations of 0.003%, 0.01%, 0.03%, and 0.1% and a cholestyramine concentration of 1.5% corresponded to 1.0 to 1.2, 3.3 to 4.2, 10 to 12, and 33 to 43 mg/kg S-8921 and to 510 to 640 mg/kg cholestyramine, respectively. Numbers of animals used for HCD control, drug treatment, and ordinary diet control were 7, 6, and 4, respectively. Data represent mean±SE. Significantly different from ordinary diet control at P<0.01 by Student's t test. *,**Significantly different from HCD group at P<0.05, P<0.01, respectively, by Dunnett's multiple comparison test.

Aortic lesions were evaluated on the basis of total cholesterol and the area covered with atheromatous plaque. The analysis was performed for 3 segments of the aorta (aortic arch, thoracic aorta, and abdominal aorta). Figure 5 shows the results for the aortic arch. S-8921 treatment significantly decreased total cholesterol contents and also tended to decrease the lesioned area, although the differences were not statistically significant (Figure 5). Almost the same results were obtained for the thoracic and abdominal aorta, although the differences in both cholesterol contents and lesioned areas were not statistically significant (data not shown).

View larger version (36K): [in this window] [in a new window]   Figure 5. Effects of S-8921 and cholestyramine on cholesterol contents and atheromatous plaque area in the aortic arch of HCD NZW rabbits. Drug administration protocol and numbers of animals were the same as described in the legend to Figure 4. Data represent mean±SE. Significantly different from ordinary diet control at P<0.01 by Student's t test. *,**Significantly different from HCD group at P<0.05, P<0.01, respectively, by Dunnett's multiple comparison test.

Atherosclerotic lesions of coronary arteries in cholesterol-fed rabbits were varied (Figure 6). We classified the severity of each lesion into 3 levels as described in Methods. All 3 levels of intimal thickening were observed in all experimental groups. S-8921 treatment significantly decreased the appearance of severe stenosis and increased the cases of no or mild stenosis (Figure 7). Cholestyramine showed similar effects (Figure 7).

View larger version (83K): [in this window] [in a new window]   Figure 6. Photomicrographs show examples of coronary atherosclerosis in HCD NZW rabbits. Left, Typical case of severe stenosis. Sample is from the HCD control group, and the severity of stenosis is 84%. Right, Typical case of no or mild stenosis. Sample is from the 0.1% S-8921 group and the severity of stenosis is 0% (x240).

View larger version (27K): [in this window] [in a new window]   Figure 7. Effects of S-8921 and cholestyramine on severity of coronary atherosclerosis in HCD NZW rabbits. Drug administration protocol and numbers of animals were as described in the legend to Figure 4. Severity of intimal thickening of coronary arteries was classified into 3 levels (none or mild, 0% to 30% stenosis; moderate, 31% to 60% stenosis; and severe, 61% to 100% stenosis), and the percentage of each stenosis level was calculated. Data represent mean±SE. *,**Significantly different from HCD group at P<0.05, P<0.01, respectively, by Dunnett's multiple comparison test.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Interruption of the enterohepatic circulation of bile acids by attenuating intestinal bile acid reabsorption is considered to be one of the best ways to lower serum cholesterol levels.³⁶ Intestinal bile acid reabsorption can be prevented by using bile acid sequestrants, such as cholestyramine and colestipol,¹⁰ or by partial ileal bypass surgery.³⁷ Both methods lead to lower serum cholesterol levels. Because IBAT plays an important role in the maintenance of intestinal bile acid reabsorption,^{12 13} its inhibition is expected to exhibit a hypocholesterolemic effect by interrupting the enterohepatic circulation of bile acids. The aim of this study was to assess the impact of IBAT inhibition on serum cholesterol level and atherosclerosis and to clarify the underlying mechanisms leading to the cholesterol decrease after IBAT inhibition. S-8921 has been demonstrated to be a novel IBAT inhibitor in hamsters and rats.^{16 17} S-8921 was shown to inhibit Na⁺-dependent [³H]taurocholate uptake in COS cells, which constitutively expressed the hamster IBAT gene and rat ileal brush-border membrane vesicles in vitro, and was also shown to markedly decrease serum cholesterol in normal hamsters and rats loaded with cholesterol and bile acid.^{16 17} Thus, we decided to use S-8921 as an IBAT inhibitor that could operate in vivo. We used rabbits as the animal models because of the resemblance of their lipid metabolism^{38 39} and atherosclerosis^{40 41} to those of humans.

We first characterized the effect of S-8921 administration on heterozygous WHHL rabbits to confirm the ability of S-8921 to inhibit IBAT in vivo in the rabbit model. Treatment with S-8921 clearly produced serum cholesterol reduction accompanied by an increase in fecal excretion of measured bile acids (Figure 1), suggesting that this drug could inhibit IBAT in vivo in rabbits. Because IBAT inhibition reduces the amount of bile acid return to the liver, increased conversion of cholesterol to bile acid and increased cholesterol synthesis in the liver was expected. To confirm this, we measured the activities of cholesterol 7-hydroxylase and HMG-CoA reductase, which are the rate-limiting enzymes of the conversion of cholesterol to bile acid and of cholesterol synthesis, respectively. Both of these liver microsomal enzyme activities were increased by S-8921 treatment (Figure 2), suggesting compensating alterations of cholesterol metabolism. Hepatic LDLR activity is considered to be the major determinant of serum cholesterol level,⁹ and 2 main classes of clinically useful hypocholesterolemic agents, HMG-CoA reductase inhibitors and bile acid sequestrants, were reported to induce it.^{5 6 7 8} S-8921 treatment in normal rabbits clearly showed increased expression of the hepatic LDLR (Figure 3) as well as the reduction of serum cholesterol. Thus, IBAT inhibition by S-8921 exhibited alterations of liver enzymes and receptor activities related to cholesterol metabolism; both could be expected from the interruption of the enterohepatic circulation of bile acids. Bile acids are known to be reabsorbed from the intestine by both passive and active mechanisms.^{42 43} Because S-8921 is an IBAT inhibitor and could not inhibit passive absorption of bile acids,¹⁷ only inhibition of the active absorption of bile acids may be sufficient to change liver cholesterol metabolism and reduce serum cholesterol.

The effect of IBAT inhibition on diet-induced hypercholesterolemia and atherosclerotic lesion formation was assessed in cholesterol-fed rabbits. Administration of S-8921 to HCD NZW rabbits clearly suppressed the development of hypercholesterolemia (Figure 4). Because 0.01% S-8921 suppressed the development of hypercholesterolemia more strongly than did 1.5% cholestyramine, S-8921 was >150x more efficacious than cholestyramine. The development of hypercholesterolemia in HCD NZW rabbits can be maintained by dietary cholesterol intake. S-8921 was reported to inhibit the absorption of cholesterol that might be due to the inhibition of bile acid reabsorption¹⁷ ; thus, the hypocholesterolemic effect of S-8921 observed in this study may have resulted from the inhibition of cholesterol absorption. S-8921 treatment also decreased the cholesterol content of the aortic arch, which may be the result of serum cholesterol reduction, although the suppressive effects of S-8921 on atheromatous plaque area were not statistically significant (Figure 5). Atherosclerosis of coronary arteries plays an important role in myocardial infarction and ischemic heart disease. S-8921 treatment dramatically reduced the severity of coronary atherosclerosis in HCD NZW rabbits (Figure 7), with the improvement being more evident than that in the aorta. Serum cholesterol reduction by pravastatin, an HMG-CoA reductase inhibitor, was reported to prevent coronary atherosclerosis but not aortic atherosclerosis in WHHL rabbits.⁴⁴ Serum cholesterol reduction may have a greater influence on the coronary arteries than on the aorta in general.

Concerning the effect of the IBAT inhibitor on serum TG level, S-8921 did not cause any increase of serum TGs in heterozygous WHHL rabbits (Table 1) and HCD NZW rabbits (Table 2). Bile acid sequestrants have been reported to increase serum TG values in human patients.^{45 46} In our study, cholestyramine did not increase serum TG levels in HCD NZW rabbits (Table 2). In former studies using other rabbit models, cholestyramine was reported to decrease serum TG in normal rabbits but to have no effect in heterozygous and homozygous WHHL rabbits.^{47 48} These findings suggest that bile acid sequestrants might not raise serum TG levels in rabbit models. It would be important to determine the effects of IBAT inhibitor on serum TG level in humans.

In conclusion, the current study investigating the impact of IBAT inhibition with the use of S-8921 produced 2 important findings. One is that IBAT inhibition changed liver cholesterol metabolism, ie, it upregulated cholesterol 7-hydroxylase and HMG-CoA reductase activities, and most important, it increased LDLR expression, which can reduce serum cholesterol. The other is that IBAT inhibition efficiently suppressed diet-induced hypercholesterolemia and atherosclerosis. We suggest that IBAT inhibitors such as S-8921 can be useful in the treatment of hypercholesterolemia.

	Acknowledgments

 
The authors thank Mie Iwai for her help with the figure illustrations.

Received December 4, 1997; accepted March 9, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention: trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374.[Abstract/Free Full Text]

2. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–3240.[Abstract/Free Full Text]

3. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298.[Abstract]

4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307.[Abstract/Free Full Text]

5. Ma PTS, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986;83:8370–8374.[Abstract/Free Full Text]

6. Reihnér E, Rudling M, Ståhlberg D, Berglund L, Ewerth S, Björkhem I, Einarsson K, Angelin B. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990;323:224–228.[Abstract]

7. Slater HR, Packard CJ, Bicker S, Shepherd J. Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit. J Biol Chem. 1980;255:10210–10213.[Abstract/Free Full Text]

8. Chao Y-S, Yamin T-T, Alberts AW. Effects of cholestyramine on low density lipoprotein binding sites on liver membranes from rabbits with endogenous hypercholesterolemia induced by a wheat starch-casein diet. J Biol Chem. 1982;257:3623–3627.[Abstract/Free Full Text]

9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47.[Free Full Text]

10. Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol. 1990;30:99–106.[Abstract]

11. Hofmann AF. The enterohepatic circulation of bile acids in health and disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. 5th ed. Philadelphia, Pa: WB Saunders Co; 1993:127–150.

12. Lack L. Properties and biological significance of the ileal bile salt transport system. Environ Health Perspect. 1979;33:79–90.[Medline] [Order article via Infotrieve]

13. Dawson PA, Oelkers P. Bile acid transporters. Curr Opin Lipidol. 1995;6:109–114.[Medline] [Order article via Infotrieve]

14. Lewis MC, Brieaddy LE, Root C. Effects of 2164U90 on ileal bile acid absorption and serum cholesterol in rats and mice. J Lipid Res. 1995;36:1098–1105.[Abstract]

15. Fears R, Brown R, Ferres H, Grenier F, Tyrrell AWR. Effects of novel bile salts on cholesterol metabolism in rats and guinea-pigs. Biochem Pharmacol. 1990;40:2029–2037.[Medline] [Order article via Infotrieve]

16. Hara S, Higaki J, Higashino K, Iwai M, Takasu N, Miyata K, Tonda K, Nagata K, Goh Y, Mizui T. S-8921, an ileal Na⁺/bile acid cotransporter inhibitor, decreases serum cholesterol in hamsters. Life Sci. 1997;60:PL365–PL370.

17. Ichihashi T, Izawa M, Miyata K, Mizui T, Hirano K, Takagishi Y. Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther. 1998;284:43–50.[Abstract/Free Full Text]

18. Martin KO, Budai K, Javitt NB. Cholesterol and 27-hydroxycholesterol 7-hydroxylation evidence for two different enzymes. J Lipid Res. 1993;34:581–588.[Abstract]

19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275.[Free Full Text]

20. Kita T, Brown MS, Watanabe Y, Goldstein JL. Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1981;78:2268–2272.[Abstract/Free Full Text]

21. Bronzert TJ, Brewer HB Jr. New micromethod for measuring cholesterol in plasma lipoprotein fractions. Clin Chem. 1977;23:2089–2098.[Abstract/Free Full Text]

22. Uchida K, Nomura Y, Kadowaki M, Arisue K, Takeuchi N, Ishikawa Y. Effects of sodium ursodeoxychotate, hydrodeoxycholate and dehydrocholate on cholesterol and bile acid metabolism in rats. J Pharm Dyn. 1983;6:346–357.[Medline] [Order article via Infotrieve]

23. Folch J, Lees M, Sloane-Stanly GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497–509.[Free Full Text]

24. Uchida K, Satoh T, Chikai T, Takase H, Nomura Y, Nakao H, Takeuchi N. Influence of cholesterol feeding on bile acid metabolism in young and aged germ-free rats. Jpn J Pharmacol. 1996;71:113–118.[Medline] [Order article via Infotrieve]

25. Okuyama S, Kokubun N, Higashidate S, Uemura D, Hirata Y. A new analytical method of individual bile acids using high performance liquid chromatography and immobilized 3-hydroxysteroid dehydrogenase in column form. Chem Lett. 1979;1443–1446.

26. Huff MW, Carroll KK. Effects of dietary protein on turnover, oxidation, and absorption of cholesterol, and on steroid excretion in rabbits. J Lipid Res. 1980;21:546–558.[Abstract]

27. Beynen AC, Meijer GW, Lemmens AG, Glatz JFC, Versluis A, Katan MB, Van Zutphen LFM. Fecal steroid excretion by rabbits hypo- or hyperresponsive to dietary cholesterol. Nutr Rep Int. 1989;40:233–238.

28. Hirano S, Akiyama Y. Absence of a hypocholesterolemic action of chitosan in high-serum-cholesterol rabbits. J Sci Food Agric. 1995;69:91–94.

29. Yokohama H, Ohtsuka I, Shiojiri H, Katayama K, Ishikawa S. A high-performance liquid chromatographic method for the assay of cholesterol 7-hydroxylase activity. Anal Biochem. 1986;157:186–190.[Medline] [Order article via Infotrieve]

30. Kuroda M, Endo A. Inhibition of in vitro cholesterol synthesis by fatty acids. Biochim Biophys Acta. 1977;486:70–81.

31. Ross AC, Go KJ, Heider JG, Rothblat GH. Selective inhibition of acyl coenzyme A: cholesterol acyltransferase by compound 58-035. J Biol Chem. 1984;259:815–819.[Abstract/Free Full Text]

32. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.[Medline] [Order article via Infotrieve]

33. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345–1353.

34. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212–221.[Medline] [Order article via Infotrieve]

35. Kume N, Kita T, Mikami A, Yokode M, Ishii K, Nagano Y, Kawai C. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (pravastatin) and cholestyramine. Circulation. 1989;79:1084–1090.[Abstract/Free Full Text]

36. Kern F Jr, Davis RA, Grundy SM. The regulation of bile acid synthesis: report of a conference. J Lipid Res. 1986;27:570–576.

37. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, POSCH group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med. 1990;323:946–955.[Abstract]

38. Chapman MJ. Comparative analysis of mammalian plasma lipoproteins. Methods Enzymol. 1986;128:70–143.[Medline] [Order article via Infotrieve]

39. Nagashima M, McLean JW, Lawn RL. Cloning and mRNA tissue distribution of rabbit cholesteryl ester transfer protein. J Lipid Res. 1988;29:1643–1649.[Abstract]

40. Tsukada T, Rosenfeld M, Ross R, Gown AM. Immunocytochemical analysis of cellular components in atherosclerotic lesions: use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis. 1986;6:601–613.[Abstract]

41. Armstrong ML, Heistad DD. Animal models of atherosclerosis. Atherosclerosis. 1990;85:15–23.[Medline] [Order article via Infotrieve]

42. Dietschy JM. Mechanisms for the intestinal absorption of bile acids. J Lipid Res. 1968;9:297–309.[Abstract]

43. Krag E, Phillips SF. Active and passive bile acid absorption in man: perfusion studies of the ileum and jejunum. J Clin Invest. 1974;53:1686–1694.

44. Watanabe Y, Ito T, Shiomi M, Tsujita Y, Kuroda M, Arai M, Fukami M, Tamura A. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta.. 1988;960:294–302.[Medline] [Order article via Infotrieve]

45. Betteridge DJ, Bhatnager D, Bing RF, Durrington PN, Evans GR, Flax H, Jay RH, Lewis-Barned N, Mann J, Matthews DR, Miller JP, Reckless JPD, Sturley R, Taylor KG. Treatment of familial hypercholesterolemia: United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ. 1992;304:1335–1338.

46. Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC, Duriez P. Comparison of the effect of fluvastatin, an hydroxy methyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism. 1995;44:1447–1454.[Medline] [Order article via Infotrieve]

47. Mamo JCL, Bowler A, Redgrave TG, Elsegood CL. Clearance of chylomicron-like lipid emulsions is increased in normal rabbits but not in heterozygous Watanabe heritable hyperlipidemic rabbits following treatment with cholestyramine or pravastatin. Clin Exp Pharmacol Physiol. 1994;21:687–694.[Medline] [Order article via Infotrieve]

48. van Niekerk JLM, Hendricks T, Gevers Leuven JA, Havekes L, de Boer HHM. The lipid-lowering effects of 3-hydroxy-3-methylglutaric acid and bile acid drainage in WHHL rabbits. Clin Sci.. 1984;67:439–444.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				P. A. Dawson, T. Lan, and A. Rao Bile acid transporters J. Lipid Res., December 1, 2009; 50(12): 2340 - 2357. [Abstract] [Full Text] [PDF]

				S. Sakamoto, H. Kusuhara, K. Horie, K. Takahashi, T. Baba, J. Ishizaki, and Y. Sugiyama Identification of the Transporters Involved in the Hepatobiliary Transport and Intestinal Efflux of Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) Glucuronide, a Pharmacologically Active Metabolite of S-8921 Drug Metab. Dispos., August 1, 2008; 36(8): 1553 - 1561. [Abstract] [Full Text] [PDF]

				S. Sakamoto, H. Kusuhara, K. Miyata, H. Shimaoka, T. Kanazu, Y. Matsuo, K. Nomura, N. Okamura, S. Hara, K. Horie, et al. Glucuronidation Converting Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a Potent Apical Sodium-Dependent Bile Acid Transporter Inhibitor, Resulting in a Hypocholesterolemic Action J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 610 - 618. [Abstract] [Full Text] [PDF]

				T. Claudel, B. Staels, and F. Kuipers The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2020 - 2030. [Abstract] [Full Text] [PDF]

				B. G. Bhat, S. R. Rapp, J. A. Beaudry, N. Napawan, D. N. Butteiger, K. A. Hall, C. L. Null, Y. Luo, and B. T. Keller Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435 J. Lipid Res., September 1, 2003; 44(9): 1614 - 1621. [Abstract] [Full Text] [PDF]

				F. Chen, L. Ma, P. A. Dawson, C. J. Sinal, E. Sehayek, F. J. Gonzalez, J. Breslow, M. Ananthanarayanan, and B. L. Shneider Liver Receptor Homologue-1 Mediates Species- and Cell Line-specific Bile Acid-dependent Negative Feedback Regulation of the Apical Sodium-dependent Bile Acid Transporter J. Biol. Chem., May 23, 2003; 278(22): 19909 - 19916. [Abstract] [Full Text] [PDF]

				M. W. Huff, D. E. Telford, J. Y. Edwards, J. R. Burnett, P. H. R. Barrett, S. R. Rapp, N. Napawan, and B. T. Keller Inhibition of the Apical Sodium-Dependent Bile Acid Transporter Reduces LDL Cholesterol and ApoB by Enhanced Plasma Clearance of LDL ApoB Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1884 - 1891. [Abstract] [Full Text] [PDF]

				J. Y. L. Chiang Bile Acid Regulation of Gene Expression: Roles of Nuclear Hormone Receptors Endocr. Rev., August 1, 2002; 23(4): 443 - 463. [Abstract] [Full Text] [PDF]

				F. Chen, L. Ma, N. Al-Ansari, and B. Shneider The Role of AP-1 in the Transcriptional Regulation of the Rat Apical Sodium-dependent Bile Acid Transporter J. Biol. Chem., October 12, 2001; 276(42): 38703 - 38714. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Higaki, J. Articles by Mizui, T. Search for Related Content PubMed PubMed Citation Articles by Higaki, J. Articles by Mizui, T.